Analyst Ratings For NASDAQ:BLPH – Bellerophon Therapeutics (NASDAQ:BLPH)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:BLPH – Bellerophon Therapeutics (NASDAQ:BLPH).
Some recent analyst ratings include
- 5/11/2018-HC Wainwright Reiterated Rating of Buy.
- 4/17/2017-Ladenburg Thalmann initiated coverage with a Buy ➝ Buy rating.
- 8/11/2016-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:BLPH – Bellerophon Therapeutics (NASDAQ:BLPH)
NASDAQ:BLPH – Bellerophon Therapeutics (NASDAQ:BLPH) has insider ownership of 57.80% and institutional ownership of 57.57%.
- On 12/9/2016 Jens Luehring, Director, bought 20,000 with an average share price of $0.56 per share and the total transaction amounting to $11,200.00.
- On 5/17/2016 Jonathan M Peacock, CEO, bought 5,000 with an average share price of $1.37 per share and the total transaction amounting to $6,850.00.
- On 12/16/2015 Jonathan M. Peacock, CEO, bought 20,300 with an average share price of $2.75 per share and the total transaction amounting to $55,825.00.
- On 8/19/2015 Jonathan M Peacock, CEO, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
- On 5/20/2015 Jonathan M Peacock, CEO, bought 5,560 with an average share price of $8.69 per share and the total transaction amounting to $48,316.40.
- On 2/19/2015 Daniel Tasse, Director, bought 25,000 with an average share price of $12.00 per share and the total transaction amounting to $300,000.00.
- On 2/19/2015 Jonathan M Peacock, CEO, bought 20,800 with an average share price of $12.00 per share and the total transaction amounting to $249,600.00.
Recent Trading Activity for NASDAQ:BLPH – Bellerophon Therapeutics (NASDAQ:BLPH)
Shares of NASDAQ:BLPH – Bellerophon Therapeutics closed the previous trading session at with 2.1710000038146973 shares trading hands.